Item 8.01 Other Events.

On January 10, 2022, PDS Biotechnology Corporation (the "Company") issued a press release announcing that it has been granted U.S Patent Application No. 15,724,818 titled "Novel HPV16 Non HLA-Restricted T-cell Vaccines, Composition and Methods of Use Thereof" by the United States Patent and Trademark Office. A copy of the press release is filed as Exhibit 99.1 hereto and incorporated by reference herein.

On January 12, 2022, the Company issued a press release announcing that the initial safety data from its VERSATILE-002 study has been accepted for presentation at the 2022 Multidisciplinary Head and Neck Cancers Symposium being held February 24-26, 2022, at the JW Marriott Phoenix Desert Ridge Resort and Spa, Phoenix, AZ.

A copy of the press release is filed as Exhibit 99.2 hereto and incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits.





(d) Exhibits.



Exhibit
 Number                                  Description

  99.1     Press Release January 10, 2022.
  99.2     Press Release January 12, 2022.
  104      Cover Page Interactive Data File - the cover page interactive date file
           does not appear in the Interactive Date File because its XBRL tags are
           embedded within the Inline XBRL document.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses